New LRRK2 variants identified in Parkinson's disease

European Journal of Neurology

Volumn 18, Issue 3, 2011, Pages 369-370

  Tan, E K ^a,b   Schapira, A H ^c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; PHOSPHOTRANSFERASE; ROTENONE;

APOPTOSIS; CELL STRESS; DROSOPHILA; EDITORIAL; ENZYME ACTIVITY; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN VARIANT; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PROTEIN-SERINE-THREONINE KINASES;

EID: 79951666248     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03163.x     Document Type: Editorial

References (20)

1. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat 2007; 28: 641-653.
2. Schapira AH. The importance of LRRK2 mutations in Parkinson disease. Arch Neurol 2006; 63: 1225-1228.
3. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-607.
4. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595-600.
5. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7: 583-590.
6. Möller JC, Rissling I, Mylius V, Höft C, Eggert KM, Oertel WH. The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease. Eur J Neurol 2008; 15: 743-745.
7. Tan EK, Zhao Y, Skipper L, et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 2007; 120: 857-863.
8. An XK, Peng R, Li T, Burgunder JM, et al. LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han Chinese from mainland China. Eur J Neurol 2008; 15: 301-305.
9. Ross OA, Wu YR, Lee MC, et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 2008; 64: 88-92.
10. Tan EK, Schapira AH. Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant. Eur J Neurol 2008; 15: 203-204.
11. Di Fonzo A, Wu-Chou YH, et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006; 7: 133-138.
12. Tan EK, Peng R, Teo YY, et al. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat 2010; 31: 561-568.
13. Zheng Y, Liu Y, Wu Q, et al. Confirmation of LRRK2 S1647T as a risk factor for Parkinson's disease in Southern China. Eur J Neurol 2010; 18: 538-540.
14. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009; 41: 1303-1307.
15. Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-1312.
16. Tan EK. The role of common genetic risk variants in Parkinson disease. Clin Genet 2007; 72: 387-393.
17. Tan EK, Peng R, Wu YR, et al. LRRK2 G2385R modulates age at onset in Parkinson's disease: a multi-center pooled analysis. Am J Med Genet B Neuropsychiatr Genet 2009; 7: 1022-1023.
18. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-1661.
19. Ng CH, Mok SZ, Koh C, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 2009; 29: 11257-11262.
20. Schapira AH, Agid Y, Barone P, et al. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol 2009; 16: 1090-1099.